Evaluating the activity of the RNA polymerase inhibitor myxopyronin B against Staphylococcus aureus

FEMS Microbiology Letters

Volumn 319, Issue 2, 2011, Pages 176-179

  Moy, Terence I ^a   Daniel, Anu ^a   Hardy, Crystal ^a   Jackson, Andrew ^a   Rehrauer, Owen ^a   Hwang, You Seok ^a   Zou, Dong ^a   Nguyen, Kien ^a   Silverman, Jared A ^a   Li, Qingyi ^a   Murphy, Christopher ^a  

^a CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

MyxB; Protein binding; Resistance

Indexed keywords

HUMAN SERUM ALBUMIN; MYXOPYRONIN B; NUCLEOTIDYLTRANSFERASE INHIBITOR; RIFAMPICIN; RNA POLYMERASE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GENE; BINDING SITE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG PROTEIN BINDING; ENZYME SUBUNIT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RPOA GENE; RPOB GENE; RPOC GENE; SIGA GENE; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DNA-DIRECTED RNA POLYMERASES; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; LACTONES; MICROBIAL SENSITIVITY TESTS; MUTATION; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

STAPHYLOCOCCUS AUREUS;

EID: 79956107891     PISSN: 03781097     EISSN: 15746968     Source Type: Journal    
DOI: 10.1111/j.1574-6968.2011.02282.x     Document Type: Article

References (13)

1. Belogurov GA, Vassylyeva MN, Sevostyanova A et al. (2009) Transcription inactivation through local refolding of the RNA polymerase structure. Nature 457: 332-335.
2. Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A & Darst SA (2001) Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104: 901-912.
3. Curry S (2009) Lessons from the crystallographic analysis of small molecule binding to human serum albumin. Drug Metab Pharmacokinet 24: 342-357.
4. Deora R & Misra TK (1996) Characterization of the primary sigma factor of Staphylococcus aureus. J Biol Chem 271: 21828-21834.
5. Doundoulakis T, Xiang AX, Lira R et al. (2004) Myxopyronin B analogs as inhibitors of RNA polymerase, synthesis and biological evaluation. Bioorg Med Chem Lett 14: 5667-5672.
6. Friedman L, Alder JD & Silverman JA (2006) Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Ch 50: 2137-2145.
7. Hu T, Schaus JV, Lam K, Palfreyman MG, Wuonola M, Gustafson G & Panek JS (1998) Total synthesis and preliminary antibacterial evaluation of the RNA polymerase inhibitors (±)-myxopyronin A and B. J Org Chem 63: 2401-2406.
8. Irschik H, Gerth K, Hofle G, Kohl W & Reichenbach H (1983) The myxopyronins, new inhibitors of bacterial RNA synthesis from Myxococcus fulvus (Myxobacterales). J Antibiot 36: 1651-1658.
9. Lira R, Agrios KA, Doundoulakis T, Simonsen KB, Webber SE & Xiang AX (2006) An efficient synthesis of (±)-myxopyronin B via versatile pyridone intermediates. Heterocycles 68: 1099-1103.
10. Lira R, Xiang AX, Doundoulakis T et al. (2007) Syntheses of novel myxopyronin B analogs as potential inhibitors of bacterial RNA polymerase. Bioorg Med Chem Lett 17: 6797-6800.
11. Mariner K, McPhillie M, Trowbridge R, Smith C, O'Neill AJ, Fishwick CW & Chopra I (2011) Activity and development of resistance to corallopyronin A, an inhibitor of RNA polymerase. Antimicrob Agents Ch. DOI: DOI: 10.1128/AAC.01742-10.
12. Marras SA, Gold B, Kramer FR, Smith I & Tyagi S (2004) Real-time measurement of in vitro transcription. Nucleic Acids Res 32: e72.
13. Mukhopadhyay J, Das K, Ismail S et al. (2008) The RNA polymerase 'switch region' is a target for inhibitors. Cell 135: 295-307.